HIV controllers: A multifactorial phenotype of spontaneous viral suppression

Clinical Immunology

Volumn 141, Issue 1, 2011, Pages 15-30

  Thèze, Jacques ^a   Chakrabarti, Lisa A ^a   Vingert, Benoît ^a   Porichis, Filippos ^b   Kaufmann, Daniel E ^b  

^a INSTITUT PASTEUR   (France)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

CD4 T cell; Controllers; HIV; Long term non progressors; Pathogenesis; Protective immunity

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CELL DEATH; CELL FUNCTION; EPIDEMIOLOGY; HEREDITY; HOST; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INNATE IMMUNITY; LYMPHOID TISSUE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; GENOME-WIDE ASSOCIATION STUDY; HIV; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; PHENOTYPE; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; VIRUS REPLICATION;

EID: 80053132664     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.07.007     Document Type: Review

References (133)

1. Deeks S.G., Walker B.D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007, 27:406-416.
2. Lambotte O., Boufassa F., Madec Y., Nguyen A., Goujard C., Meyer L., Rouzioux C., Venet A., Delfraissy J.F. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin. Infect. Dis. 2005, 41:1053-1056.
3. Okulicz J.F., Marconi V.C., Landrum M.L., Wegner S., Weintrob A., Ganesan A., Hale B., Crum-Cianflone N., Delmar J., Barthel V., Quinnan G., Agan B.K., Dolan M.J. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J. Infect. Dis. 2009, 200:1714-1723.
4. Pereyra F., Palmer S., Miura T., Block B.L., Wiegand A., Rothchild A.C., Baker B., Rosenberg R., Cutrell E., Seaman M.S., Coffin J.M., Walker B.D. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J. Infect. Dis. 2009, 200:984-990.
5. Hatano H., Delwart E.L., Norris P.J., Lee T.H., Dunn-Williams J., Hunt P.W., Hoh R., Stramer S.L., Linnen J.M., McCune J.M., Martin J.N., Busch M.P., Deeks S.G. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J. Virol. 2009, 83:329-335.
6. Kaufmann D.E., Kavanagh D.G., Pereyra F., Zaunders J.J., Mackey E.W., Miura T., Palmer S., Brockman M., Rathod A., Piechocka-Trocha A., Baker B., Zhu B., Le Gall S., Waring M.T., Ahern R., Moss K., Kelleher A.D., Coffin J.M., Freeman G.J., Rosenberg E.S., Walker B.D. Upregulation of CTLA-4 by HIV-specific CD4(+) T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 2007, 8:1246-1254.
7. Pereyra F., Jia X., McLaren P.J., Telenti A., de Bakker P.I., Walker B.D., Ripke S., Brumme C.J., Pulit S.L., Carrington M., Kadie C.M., Carlson J.M., Heckerman D., Graham R.R., Plenge R.M., Deeks S.G., Gianniny L., Crawford G., Sullivan J., Gonzalez E., Davies L., Camargo A., Moore J.M., Beattie N., Gupta S., Crenshaw A., Burtt N.P., Guiducci C., Gupta N., Gao X., Qi Y., Yuki Y., Piechocka-Trocha A., Cutrell E., Rosenberg R., Moss K.L., Lemay P., O'Leary J., Schaefer T., Verma P., Toth I., Block B., Baker B., Rothchild A., Lian J., Proudfoot J., Alvino D.M., Vine S., Addo M.M., Allen T.M., Altfeld M., Henn M.R., Le Gall S., Streeck H., Haas D.W., Kuritzkes D.R., Robbins G.K., Shafer R.W., Gulick R.M., Shikuma C.M., Haubrich R., Riddler S., Sax P.E., Daar E.S., Ribaudo H.J., Agan B., Agarwal S., Ahern R.L., Allen B.L., Altidor S., Altschuler E.L., Ambardar S., Anastos K., Anderson B., Anderson V., Andrady U., Antoniskis D., Bangsberg D., Barbaro D., Barrie W., Bartczak J., Barton S., Basden P., Basgoz N., Bazner S., Bellos N.C., Benson A.M., Berger J., Bernard N.F., Bernard A.M., Birch C., Bodner S.J., Bolan R.K., Boudreaux E.T., Bradley M., Braun J.F., Brndjar J.E., Brown S.J., Brown K., Brown S.T., Burack J., Bush L.M., Cafaro V., Campbell O., Campbell J., Carlson R.H., Carmichael J.K., Casey K.K., Cavacuiti C., Celestin G., Chambers S.T., Chez N., Chirch L.M., Cimoch P.J., Cohen D., Cohn L.E., Conway B., Cooper D.A., Cornelson B., Cox D.T., Cristofano M.V., Cuchural G., Czartoski J.L., Dahman J.M., Daly J.S., Davis B.T., Davis K., Davod S.M., DeJesus E., Dietz C.A., Dunham E., Dunn M.E., Ellerin T.B., Eron J.J., Fangman J.J., Farel C.E., Ferlazzo H., Fidler S., Fleenor-Ford A., Frankel R., Freedberg K.A., French N.K., Fuchs J.D., Fuller J.D., Gaberman J., Gallant J.E., Gandhi R.T., Garcia E., Garmon D., Gathe J.C., Gaultier C.R., Gebre W., Gilman F.D., Gilson I., Goepfert P.A., Gottlieb M.S., Goulston C., Groger R.K., Gurley T.D., Haber S., Hardwicke R., Hardy W.D., Harrigan P.R., Hawkins T.N., Heath S., Hecht F.M., Henry W.K., Hladek M., Hoffman R.P., Horton J.M., Hsu R.K., Huhn G.D., Hunt P., Hupert M.J., Illeman M.L., Jaeger H., Jellinger R.M., John M., Johnson J.A., Johnson K.L., Johnson H., Johnson K., Joly J., Jordan W.C., Kauffman C.A., Khanlou H., Killian R.K., Kim A.Y., Kim D.D., Kinder C.A., Kirchner J.T., Kogelman L., Kojic E.M., Korthuis P.T., Kurisu W., Kwon D.S., LaMar M., Lampiris H., Lanzafame M., Lederman M.M., Lee D.M., Lee J.M., Lee M.J., Lee E.T., Lemoine J., Levy J.A., Llibre J.M., Liguori M.A., Little S.J., Liu A.Y., Lopez A.J., Loutfy M.R., Loy D., Mohammed D.Y., Man A., Mansour M.K., Marconi V.C., Markowitz M., Marques R., Martin J.N., Martin H.L., Mayer K.H., McElrath M.J., McGhee T.A., McGovern B.H., McGowan K., McIntyre D., McLeod G.X., Menezes P., Mesa G., Metroka C.E., Meyer-Olson D., Miller A.O., Montgomery K., Mounzer K.C., Nagami E.H., Nagin I., Nahass R.G., Nelson M.O., Nielsen C., Norene D.L., O'Connor D.H., Ojikutu B.O., Okulicz J., Oladehin O.O., Oldfield E.C., Olender S.A., Ostrowski M., Owen W.F., Pae E., Parsonnet J., Pavlatos A.M., Perlmutter A.M., Pierce M.N., Pincus J.M., Pisani L., Price L.J., Proia L., Prokesch R.C., Pujet H.C., Ramgopal M., Rathod A., Rausch M., Ravishankar J., Rhame F.S., Richards C.S., Richman D.D., Rodes B., Rodriguez M., Rose R.C., Rosenberg E.S., Rosenthal D., Ross P.E., Rubin D.S., Rumbaugh E., Saenz L., Salvaggio M.R., Sanchez W.C., Sanjana V.M., Santiago S., Schmidt W., Schuitemaker H., Sestak P.M., Shalit P., Shay W., Shirvani V.N., Silebi V.I., Sizemore J.M., Skolnik P.R., Sokol-Anderson M., Sosman J.M., Stabile P., Stapleton J.T., Starrett S., Stein F., Stellbrink H.J., Sterman F.L., Stone V.E., Stone D.R., Tambussi G., Taplitz R.A., Tedaldi E.M., Theisen W., Torres R., Tosiello L., Tremblay C., Tribble M.A., Trinh P.D., Tsao A., Ueda P., Vaccaro A., Valadas E., Vanig T.J., Vecino I., Vega V.M., Veikley W., Wade B.H., Walworth C., Wanidworanun C., Ward D.J., Warner D.A., Weber R.D., Webster D., Weis S., Wheeler D.A., White D.J., Wilkins E., Winston A., Wlodaver C.G., van't Wout A., Wright D.P., Yang O.O., Yurdin D.L., Zabukovic B.W., Zachary K.C., Zeeman B., Zhao M. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010, 330:1551-1557.
8. Fellay J., Shianna K.V., Ge D., Colombo S., Ledergerber B., Weale M., Zhang K., Gumbs C., Castagna A., Cossarizza A., Cozzi-Lepri A., De Luca A., Easterbrook P., Francioli P., Mallal S., Martinez-Picado J., Miro J.M., Obel N., Smith J.P., Wyniger J., Descombes P., Antonarakis S.E., Letvin N.L., McMichael A.J., Haynes B.F., Telenti A., Goldstein D.B. A whole-genome association study of major determinants for host control of HIV-1. Science 2007, 317:944-947.
9. Kim A.Y., Kuntzen T., Timm J., Nolan B.E., Baca M.A., Reyor L.L., Berical A.C., Feller A.J., Johnson K.L., Schulze zur Wiesch J., Robbins G.K., Chung R.T., Walker B.D., Carrington M., Allen T.M., Lauer G.M. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 2011, 140:686-696. (e681).
10. Migueles S.A., Sabbaghian M.S., Shupert W.L., Bettinotti M.P., Marincola F.M., Martino L., Hallahan C.W., Selig S.M., Schwartz D., Sullivan J., Connors M. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. USA 2000, 97:2709-2714.
11. Fang G., Kuiken C., Weiser B., Rowland-Jones S., Plummer F., Chen C.H., Kaul R., Anzala A.O., Bwayo J., Kimani J., Philpott S.M., Kitchen C., Sinsheimer J.S., Gaschen B., Lang D., Shi B., Kemal K.S., Rostron T., Brunner C., Beddows S., Sattenau Q., Paxinos E., Oyugi J., Burger H. Long-term survivors in Nairobi: complete HIV-1 RNA sequences and immunogenetic associations. J. Infect. Dis. 2004, 190:697-701.
12. Kulkarni S., Savan R., Qi Y., Gao X., Yuki Y., Bass S.E., Martin M.P., Hunt P., Deeks S.G., Telenti A., Pereyra F., Goldstein D., Wolinsky S., Walker B., Young H.A., Carrington M. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature 2011, 472:495-498.
13. Goujard C., Chaix M.L., Lambotte O., Deveau C., Sinet M., Guergnon J., Courgnaud V., Rouzioux C., Delfraissy J.F., Venet A., Meyer L. Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established?. Clin. Infect. Dis. 2009, 49:982-986.
14. Miura T., Brumme Z.L., Brockman M.A., Rosato P., Sela J., Brumme C.J., Pereyra F., Kaufmann D.E., Trocha A., Block B.L., Daar E.S., Connick E., Jessen H., Kelleher A.D., Rosenberg E., Markowitz M., Schafer K., Vaida F., Iwamoto A., Little S., Walker B.D. Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J. Virol. 2010, 84:7581-7591.
15. Harrison L., Castro H., Cane P., Pillay D., Booth C., Phillips A., Geretti A.M., Dunn D. The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS 2010, 24:1917-1922.
16. Troyer R.M., McNevin J., Liu Y., Zhang S.C., Krizan R.W., Abraha A., Tebit D.M., Zhao H., Avila S., Lobritz M.A., McElrath M.J., Le Gall S., Mullins J.I., Arts E.J. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog. 2009, 5:e1000365.
17. Goepfert P.A., Lumm W., Farmer P., Matthews P., Prendergast A., Carlson J.M., Derdeyn C.A., Tang J., Kaslow R.A., Bansal A., Yusim K., Heckerman D., Mulenga J., Allen S., Goulder P.J., Hunter E. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J. Exp. Med. 2008, 205:1009-1017.
18. Deacon N.J., Tsykin A., Solomon A., Smith K., Ludford-Menting M., Hooker D.J., McPhee D.A., Greenway A.L., Ellett A., Chatfield C., et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995, 270:988-991.
19. Miura T., Brockman M.A., Brumme Z.L., Brumme C.J., Pereyra F., Trocha A., Block B.L., Schneidewind A., Allen T.M., Heckerman D., Walker B.D. HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J. Virol. 2009, 83:140-149.
20. Lassen K.G., Lobritz M.A., Bailey J.R., Johnston S., Nguyen S., Lee B., Chou T., Siliciano R.F., Markowitz M., Arts E.J. Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog. 2009, 5:e1000377.
21. Bailey J.R., O'Connell K., Yang H.C., Han Y., Xu J., Jilek B., Williams T.M., Ray S.C., Siliciano R.F., Blankson J.N. Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J. Virol. 2008, 82:7395-7410.
22. Lamine A., Caumont-Sarcos A., Chaix M.L., Saez-Cirion A., Rouzioux C., Delfraissy J.F., Pancino G., Lambotte O. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS 2007, 21:1043-1045.
23. Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Allikmets R., Goedert J.J., Buchbinder S.P., Vittinghoff E., Gomperts E., Donfield S., Vlahov D., Kaslow R., Saah A., Rinaldo C., Detels R., O'Brien S.J. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273:1856-1862.
24. Pereyra F., Addo M.M., Kaufmann D.E., Liu Y., Miura T., Rathod A., Baker B., Trocha A., Rosenberg R., Mackey E., Ueda P., Lu Z., Cohen D., Wrin T., Petropoulos C.J., Rosenberg E.S., Walker B.D. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 2008, 197:563-571.
25. Hrecka K., Hao C., Gierszewska M., Swanson S.K., Kesik-Brodacka M., Srivastava S., Florens L., Washburn M.P., Skowronski J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011, 474:658-661.
26. Julg B., Pereyra F., Buzon M.J., Piechocka-Trocha A., Clark M.J., Baker B.M., Lian J., Miura T., Martinez-Picado J., Addo M.M., Walker B.D. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin. Infect. Dis. 2010, 51:233-238.
27. Rabi S.A., O'Connell K.A., Nikolaeva D., Bailey J.R., Jilek B.L., Shen L., Page K.R., Siliciano R.F., Blankson J.N. Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection. J. Virol. 2011, 85:979-986.
28. Chen H., Li C., Huang J., Cung T., Seiss K., Beamon J., Carrington M.F., Porter L.C., Burke P.S., Yang Y., Ryan B.J., Liu R., Weiss R.H., Pereyra F., Cress W.D., Brass A.L., Rosenberg E.S., Walker B.D., Yu X.G., Lichterfeld M. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J. Clin. Invest. 2011, 121:1549-1560.
29. Saez-Cirion A., Hamimi C., Bergamaschi A., David A., Versmisse P., Melard A., Boufassa F., Barre-Sinoussi F., Lambotte O., Rouzioux C., Pancino G. Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood 2011, 118:955-964.
30. Okoye A., Meier-Schellersheim M., Brenchley J.M., Hagen S.I., Walker J.M., Rohankhedkar M., Lum R., Edgar J.B., Planer S.L., Legasse A., Sylwester A.W., Piatak M., Lifson J.D., Maino V.C., Sodora D.L., Douek D.C., Axthelm M.K., Grossman Z., Picker L.J. Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J. Exp. Med. 2007, 204:2171-2185.
31. Douek D.C., Picker L.J., Koup R.A. T cell dynamics in HIV-1 infection. Annu. Rev. Immunol. 2003, 21:265-304.
32. van Grevenynghe J., Procopio F.A., He Z., Chomont N., Riou C., Zhang Y., Gimmig S., Boucher G., Wilkinson P., Shi Y., Yassine-Diab B., Said E.A., Trautmann L., El Far M., Balderas R.S., Boulassel M.R., Routy J.P., Haddad E.K., Sekaly R.P. Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat. Med. 2008, 14:266-274.
33. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat. Immunol. 2008, 9:503-510.
34. Berger C.T., Alter G. Natural killer cells in spontaneous control of HIV infection. Curr. Opin. HIV AIDS 2011, 6:208-213.
35. Martin M.P., Gao X., Lee J.H., Nelson G.W., Detels R., Goedert J.J., Buchbinder S., Hoots K., Vlahov D., Trowsdale J., Wilson M., O'Brien S.J., Carrington M. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 2002, 31:429-434.
36. Martin M.P., Qi Y., Gao X., Yamada E., Martin J.N., Pereyra F., Colombo S., Brown E.E., Shupert W.L., Phair J., Goedert J.J., Buchbinder S., Kirk G.D., Telenti A., Connors M., O'Brien S.J., Walker B.D., Parham P., Deeks S.G., McVicar D.W., Carrington M. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 2007, 39:733-740.
37. Vieillard V., Fausther-Bovendo H., Samri A., Debre P. Specific phenotypic and functional features of natural killer cells from HIV-infected long-term nonprogressors and HIV controllers. J. Acquir. Immune Defic. Syndr. 2010, 53:564-573.
38. Lambotte O., Ferrari G., Moog C., Yates N.L., Liao H.X., Parks R.J., Hicks C.B., Owzar K., Tomaras G.D., Montefiori D.C., Haynes B.F., Delfraissy J.F. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009, 23:897-906.
39. Schmidt B., Fujimura S.H., Martin J.N., Levy J.A. Variations in plasmacytoid dendritic cell (PDC) and myeloid dendritic cell (MDC) levels in HIV-infected subjects on and off antiretroviral therapy. J. Clin. Immunol. 2006, 26:55-64.
40. Nascimbeni M., Perie L., Chorro L., Diocou S., Kreitmann L., Louis S., Garderet L., Fabiani B., Berger A., Schmitz J., Marie J.P., Molina T.J., Pacanowski J., Viard J.P., Oksenhendler E., Beq S., Abehsira-Amar O., Cheynier R., Hosmalin A. Plasmacytoid dendritic cells accumulate in spleens from chronically HIV-infected patients but barely participate in interferon-alpha expression. Blood 2009, 113:6112-6119.
41. Huang J., Burke P.S., Cung T.D., Pereyra F., Toth I., Walker B.D., Borges L., Lichterfeld M., Yu X.G. Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers. J. Virol. 2010, 84:9463-9471.
42. Virgin H.W., Wherry E.J., Ahmed R. Redefining chronic viral infection. Cell 2009, 138:30-50.
43. Nakanishi Y., Lu B., Gerard C., Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 2009, 462:510-513.
44. Theze J. The Cytokine Network and Immune Functions 1999, Oxford University Press.
45. King C., Tangye S.G., Mackay C.R. T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu. Rev. Immunol. 2008, 26:741-766.
46. McCune J.M. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 2001, 410:974-979.
47. Potter S.J., Lacabaratz C., Lambotte O., Perez-Patrigeon S., Vingert B., Sinet M., Colle J.H., Urrutia A., Scott-Algara D., Boufassa F., Delfraissy J.F., Theze J., Venet A., Chakrabarti L.A. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J. Virol. 2007, 81:13904-13915.
48. Younes S.A., Yassine-Diab B., Dumont A.R., Boulassel M.R., Grossman Z., Routy J.P., Sekaly R.P. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J. Exp. Med. 2003, 198:1909-1922.
49. Emu B., Sinclair E., Favre D., Moretto W.J., Hsue P., Hoh R., Martin J.N., Nixon D.F., McCune J.M., Deeks S.G. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J. Virol. 2005, 79:14169-14178.
50. David D., Bani L., Moreau J.L., Treilhou M.P., Nakarai T., Joussemet M., Ritz J., Dupont B., Pialoux G., Theze J. Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. Proc. Natl. Acad. Sci. USA 1998, 95:11348-11353.
51. Kryworuchko M., Pasquier V., Keller H., David D., Goujard C., Gilquin J., Viard J.P., Joussemet M., Delfraissy J.F., Theze J. Defective interleukin-2-dependent STAT5 signalling in CD8 T lymphocytes from HIV-positive patients: restoration by antiretroviral therapy. AIDS 2004, 18:421-426.
52. Kryworuchko M., Pasquier V., Theze J. Human immunodeficiency virus-1 envelope glycoproteins and anti-CD4 antibodies inhibit interleukin-2-induced Jak/STAT signalling in human CD4 T lymphocytes. Clin. Exp. Immunol. 2003, 131:422-427.
53. Dunham R.M., Cervasi B., Brenchley J.M., Albrecht H., Weintrob A., Sumpter B., Engram J., Gordon S., Klatt N.R., Frank I., Sodora D.L., Douek D.C., Paiardini M., Silvestri G. CD127 and CD25 expression defines CD4+ T cell subsets that are differentially depleted during HIV infection. J. Immunol. 2008, 180:5582-5592.
54. Paiardini M., Cervasi B., Albrecht H., Muthukumar A., Dunham R., Gordon S., Radziewicz H., Piedimonte G., Magnani M., Montroni M., Kaech S.M., Weintrob A., Altman J.D., Sodora D.L., Feinberg M.B., Silvestri G. Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals. J. Immunol. 2005, 174:2900-2909.
55. Rethi B., Fluur C., Atlas A., Krzyzowska M., Mowafi F., Grutzmeier S., De Milito A., Bellocco R., Falk K.I., Rajnavolgyi E., Chiodi F. Loss of IL-7Ralpha is associated with CD4 T-cell depletion, high interleukin-7 levels and CD28 down-regulation in HIV infected patients. AIDS 2005, 19:2077-2086.
56. Juffroy O., Bugault F., Lambotte O., Landires I., Viard J.P., Niel L., Fontanet A., Delfraissy J.F., Theze J., Chakrabarti L.A. Dual mechanism of impairment of interleukin-7 (IL-7) responses in human immunodeficiency virus infection: decreased IL-7 binding and abnormal activation of the JAK/STAT5 pathway. J. Virol. 2010, 84:96-108.
57. Chahroudi A., Silvestri G. Interleukin-7 in HIV pathogenesis and therapy. Eur. Cytokine Netw. 2010, 21:202-207.
58. Zeng M., Smith A.J., Wietgrefe S.W., Southern P.J., Schacker T.W., Reilly C.S., Estes J.D., Burton G.F., Silvestri G., Lifson J.D., Carlis J.V., Haase A.T. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J. Clin. Invest. 2011, 121:998-1008.
59. Levy Y., Lacabaratz C., Weiss L., Viard J.P., Goujard C., Lelievre J.D., Boue F., Molina J.M., Rouzioux C., Avettand-Fenoel V., Croughs T., Beq S., Thiebaut R., Chene G., Morre M., Delfraissy J.F. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J. Clin. Invest. 2009, 119:997-1007.
60. Sereti I., Dunham R.M., Spritzler J., Aga E., Proschan M.A., Medvik K., Battaglia C.A., Landay A.L., Pahwa S., Fischl M.A., Asmuth D.M., Tenorio A.R., Altman J.D., Fox L., Moir S., Malaspina A., Morre M., Buffet R., Silvestri G., Lederman M.M. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009, 113:6304-6314.
61. Pellegrini M., Calzascia T., Toe J.G., Preston S.P., Lin A.E., Elford A.R., Shahinian A., Lang P.A., Lang K.S., Morre M., Assouline B., Lahl K., Sparwasser T., Tedder T.F., Paik J.H., DePinho R.A., Basta S., Ohashi P.S., Mak T.W. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 2011, 144:601-613.
62. Douek D.C., Brenchley J.M., Betts M.R., Ambrozak D.R., Hill B.J., Okamoto Y., Casazza J.P., Kuruppu J., Kunstman K., Wolinsky S., Grossman Z., Dybul M., Oxenius A., Price D.A., Connors M., Koup R.A. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002, 417:95-98.
63. Porichis F., Kaufmann D.E. HIV-specific CD4 T cells and immune control of viral replication. Curr. Opin. HIV AIDS 2011, 6:174-180.
64. Betts M.R., Ambrozak D.R., Douek D.C., Bonhoeffer S., Brenchley J.M., Casazza J.P., Koup R.A., Picker L.J. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 2001, 75:11983-11991.
65. Harari A., Petitpierre S., Vallelian F., Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2004, 103:966-972.
66. Yi J.S., Cox M.A., Zajac A.J. Interleukin-21: a multifunctional regulator of immunity to infections. Microbes Infect. 2010, 12:1111-1119.
67. Iannello A., Tremblay C., Routy J.P., Boulassel M.R., Toma E., Ahmad A. Decreased levels of circulating IL-21 in HIV-infected AIDS patients: correlation with CD4+ T-cell counts. Viral Immunol. 2008, 21:385-388.
68. Iannello A., Boulassel M.R., Samarani S., Debbeche O., Tremblay C., Toma E., Routy J.P., Ahmad A. Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study. J. Immunol. 2010, 184:114-126.
69. Yue F.Y., Lo C., Sakhdari A., Lee E.Y., Kovacs C.M., Benko E., Liu J., Song H., Jones R.B., Sheth P., Chege D., Kaul R., Ostrowski M.A. HIV-specific IL-21 producing CD4+ T cells are induced in acute and chronic progressive HIV infection and are associated with relative viral control. J. Immunol. 2010, 185:498-506.
70. Chevalier M.F., Julg B., Pyo A., Flanders M., Ranasinghe S., Soghoian D.Z., Kwon D.S., Rychert J., Lian J., Muller M.I., Cutler S., McAndrew E., Jessen H., Pereyra F., Rosenberg E.S., Altfeld M., Walker B.D., Streeck H. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J. Virol. 2011, 85:733-741.
71. Williams L.D., Bansal A., Sabbaj S., Heath S.L., Song W., Tang J., Zajac A.J., Goepfert P.A. Interleukin-21-producing HIV-1-specific CD8 T cells are preferentially seen in elite controllers. J. Virol. 2011, 85:2316-2324.
72. Vingert B., Perez-Patrigeon S., Jeannin P., Lambotte O., Boufassa F., Lemaitre F., Kwok W.W., Theodorou I., Delfraissy J.F., Theze J., Chakrabarti L.A. HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity. PLoS Pathog. 2010, 6:e1000780.
73. Kaufmann D.E., Bailey P., Sidney J., Wagner B., Norris P.J., Johnston M.N., Cosimi L., Addo M.M., Lichterfeld M., Altfeld M., Frahm N., Brander C., Sette A., Walker B.D., Rosenberg E.S. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J. Virol. 2004, 78:4463-4477.
74. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., Mackey E.W., Miller J.D., Leslie A.J., DePierres C., Mncube Z., Duraiswamy J., Zhu B., Eichbaum Q., Altfeld M., Wherry E.J., Coovadia H.M., Goulder P.J., Klenerman P., Ahmed R., Freeman G.J., Walker B.D. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
75. D'Souza M., Fontenot A.P., Mack D.G., Lozupone C., Dillon S., Meditz A., Wilson C.C., Connick E., Palmer B.E. Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. J. Immunol. 2007, 179:1979-1987.
76. Porichis F., Kwon D.S., Zupkosky J., Tighe D.P., McMullen A., Brockman M.A., Pavlik D.F., Rodriguez-Garcia M., Pereyra F., Freeman G.J., Kavanagh D.G., Kaufmann D.E. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood 2011, 118:965-974.
77. Brockman M.A., Kwon D.S., Tighe D.P., Pavlik D.F., Rosato P.C., Sela J., Porichis F., Le Gall S., Waring M.T., Moss K., Jessen H., Pereyra F., Kavanagh D.G., Walker B.D., Kaufmann D.E. IL-10 is upregulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood 2009, 114:346-356.
78. Kaufmann D.E., Walker B.D. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J. Immunol. 2009, 182:5891-5897.
79. Kwon D.S., Kaufmann D.E. Protective and detrimental roles of IL-10 in HIV pathogenesis. Eur. Cytokine Netw. 2010, 21:208-214.
80. Malhotra U., Holte S., Dutta S., Berrey M.M., Delpit E., Koelle D.M., Sette A., Corey L., McElrath M.J. Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J. Clin. Invest. 2001, 107:505-517.
81. Ferre A.L., Hunt P.W., McConnell D.H., Morris M.M., Garcia J.C., Pollard R.B., Yee H.F., Martin J.N., Deeks S.G., Shacklett B.L. HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J. Virol. 2010, 84:11020-11029.
82. Julg B., Moodley E.S., Qi Y., Ramduth D., Reddy S., Mncube Z., Gao X., Goulder P.J., Detels R., Ndung'u T., Walker B.D., Carrington M. Possession of HLA class II DRB1*1303 associates with reduced viral loads in chronic HIV-1 clade C and B infection. J. Infect. Dis. 2010, 203:803-809.
83. Hatton R.D., Weaver C.T. Duality in the Th17-Treg developmental decision. Biol. Reprod. 2009, 1. (F1000).
84. Hartigan-O'connor J.D., Hirao L.A., McCune J.M., Dandekar S. Th17 cells and regulatory T cells in elite control over HIV and SIV. Curr. Opin. HIV AIDS 2010, 6:221-227.
85. Schulze Zur Wiesch J., Thomssen A., Hartjen P., Toth I., Lehmann C., Meyer-Olson D., Colberg K., Frerk S., Babikir D., Schmiedel S., Degen O., Mauss S., Rockstroh J., Staszewski S., Khaykin P., Strasak A., Lohse A.W., Fatkenheuer G., Hauber J., van Lunzen J. Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. J. Virol. 2011, 85:1287-1297.
86. Owen R.E., Heitman J.W., Hirschkorn D.F., Lanteri M.C., Biswas H.H., Martin J.N., Krone M.R., Deeks S.G., Norris P.J. HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS 2010, 24:1095-1105.
87. Nilsson J., Boasso A., Velilla P.A., Zhang R., Vaccari M., Franchini G., Shearer G.M., Andersson J., Chougnet C. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 2006, 108:3808-3817.
88. Favre D., Lederer S., Kanwar B., Ma Z.M., Proll S., Kasakow Z., Mold J., Swainson L., Barbour J.D., Baskin C.R., Palermo R., Pandrea I., Miller C.J., Katze M.G., McCune J.M. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 2009, 5:e1000295.
89. Favre D., Mold J., Hunt P.W., Kanwar B., Loke P., Seu L., Barbour J.D., Lowe M.M., Jayawardene A., Aweeka F., Huang Y., Douek D.C., Brenchley J.M., Martin J.N., Hecht F.M., Deeks S.G., McCune J.M. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci. Transl. Med. 2010, 2:32ra36.
90. Brandt L., Benfield T., Mens H., Clausen L.N., Katzenstein T.L., Fomsgaard A., Karlsson I. Low level of regulatory T-cells and maintenance of balance between regulatory T-cells and TH17 cells in HIV-1-infected elite controllers. J. Acquir. Immune Defic. Syndr. 2011, 57:101-108.
91. Kosmrlj A., Read E.L., Qi Y., Allen T.M., Altfeld M., Deeks S.G., Pereyra F., Carrington M., Walker B.D., Chakraborty A.K. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 2010, 465:350-354.
92. Miura T., Brockman M.A., Schneidewind A., Lobritz M., Pereyra F., Rathod A., Block B.L., Brumme Z.L., Brumme C.J., Baker B., Rothchild A.C., Li B., Trocha A., Cutrell E., Frahm N., Brander C., Toth I., Arts E.J., Allen T.M., Walker B.D. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J. Virol. 2009, 83:2743-2755.
93. Lopez-Vazquez A., Mina-Blanco A., Martinez-Borra J., Njobvu P.D., Suarez-Alvarez B., Blanco-Gelaz M.A., Gonzalez S., Rodrigo L., Lopez-Larrea C. Interaction between KIR3DL1 and HLA-B*57 supertype alleles influences the progression of HIV-1 infection in a Zambian population. Hum. Immunol. 2005, 66:285-289.
94. Migueles S.A., Laborico A.C., Shupert W.L., Sabbaghian M.S., Rabin R., Hallahan C.W., Van Baarle D., Kostense S., Miedema F., McLaughlin M., Ehler L., Metcalf J., Liu S., Connors M. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 2002, 3:1061-1068.
95. Hersperger A.R., Pereyra F., Nason M., Demers K., Sheth P., Shin L.Y., Kovacs C.M., Rodriguez B., Sieg S.F., Teixeira-Johnson L., Gudonis D., Goepfert P.A., Lederman M.M., Frank I., Makedonas G., Kaul R., Walker B.D., Betts M.R. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 2010, 6:e1000917.
96. Harari A., Enders F.B., Cellerai C., Bart P.A., Pantaleo G. Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure. J. Virol. 2009, 83:2862-2871.
97. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., Lederman M.M., Benito J.M., Goepfert P.A., Connors M., Roederer M., Koup R.A. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T-cells. Blood 2006, 107:4781-4789.
98. Saez-Cirion A., Lacabaratz C., Lambotte O., Versmisse P., Urrutia A., Boufassa F., Barre-Sinoussi F., Delfraissy J.F., Sinet M., Pancino G., Venet A. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. USA 2007, 104:6776-6781.
99. Saez-Cirion A., Sinet M., Shin S.Y., Urrutia A., Versmisse P., Lacabaratz C., Boufassa F., Avettand-Fenoel V., Rouzioux C., Delfraissy J.F., Barre-Sinoussi F., Lambotte O., Venet A., Pancino G. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J. Immunol. 2009, 182:7828-7837.
100. Migueles S.A., Weeks K.A., Nou E., Berkley A.M., Rood J.E., Osborne C.M., Hallahan C.W., Cogliano-Shutta N.A., Metcalf J.A., McLaughlin M., Kwan R., Mican J.M., Davey R.T., Connors M. Defective HIV-specific CD8+ T cell polyfunctionality, proliferation and cytotoxicity are not restored by antiretroviral therapy. J. Virol. 2009, 83:11876-11889.
101. Quigley M., Pereyra F., Nilsson B., Porichis F., Fonseca C., Eichbaum Q., Julg B., Jesneck J.L., Brosnahan K., Imam S., Russell K., Toth I., Piechocka-Trocha A., Dolfi D., Angelosanto J., Crawford A., Shin H., Kwon D.S., Zupkosky J., Francisco L., Freeman G.J., Wherry E.J., Kaufmann D.E., Walker B.D., Ebert B., Haining W.N. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat. Med. 2010, 16:1147-1151.
102. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., Reddy S., de Pierres C., Mncube Z., Mkhwanazi N., Bishop K., van der Stok M., Nair K., Khan N., Crawford H., Payne R., Leslie A., Prado J., Prendergast A., Frater J., McCarthy N., Brander C., Learn G.H., Nickle D., Rousseau C., Coovadia H., Mullins J.I., Heckerman D., Walker B.D., Goulder P. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 2007, 13:46-53.
103. Sacha J.B., Chung C., Rakasz E.G., Spencer S.P., Jonas A.K., Bean A.T., Lee W., Burwitz B.J., Stephany J.J., Loffredo J.T., Allison D.B., Adnan S., Hoji A., Wilson N.A., Friedrich T.C., Lifson J.D., Yang O.O., Watkins D.I. Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J. Immunol. 2007, 178:2746-2754.
104. Bennett M.S., Joseph A., Ng H.L., Goldstein H., Yang O.O. Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes. AIDS 2010, 24:2619-2628.
105. Lichterfeld M., Yu X.G., Mui S.K., Williams K.L., Trocha A., Brockman M.A., Allgaier R.L., Waring M.T., Koibuchi T., Johnston M.N., Cohen D., Allen T.M., Rosenberg E.S., Walker B.D., Altfeld M. Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J. Virol. 2007, 81:4199-4214.
106. Almeida J.R., Price D.A., Papagno L., Arkoub Z.A., Sauce D., Bornstein E., Asher T.E., Samri A., Schnuriger A., Theodorou I., Costagliola D., Rouzioux C., Agut H., Marcelin A.G., Douek D., Autran B., Appay V. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 2007, 204:2473-2485.
107. Berger C.T., Frahm N., Price D.A., Mothe B., Ghebremichael M., Hartman K.L., Henry L.M., Brenchley J.M., Ruff L.E., Venturi V., Pereyra F., Sidney J., Sette A., Douek D.C., Walker B.D., Kaufmann D.E., Brander C. High functional avidity CTL responses to HLA-B-restricted Gag-derived epitopes associate with relative HIV control. J. Virol. 2011, [Electronic publication ahead of print].
108. Pereyra F., Addo M.M., Kaufmann D.E., Miura T., Rathod A., Baker B., M.E.W., Trocha A., Ueda P., Rosenberg R., Cohen D., Stone D.R., Liu Y., Wrin T., Buchbinder S., Petropoulos C.J., Rosenberg E.S., Walker B.D. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 2008, 197:563-571.
109. Bailey J.R., Lassen K.G., Yang H.C., Quinn T.C., Ray S.C., Blankson J.N., Siliciano R.F. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J. Virol. 2006, 80:4758-4770.
110. Sajadi M.M., Guan Y., Devico A.L., Seaman M.S., Hossain M., Lewis G.K., Redfield R.R. Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J. Acquir. Immune Defic. Syndr. 2011, 57:9-15.
111. Doria-Rose N.A., Klein R.M., Daniels M.G., O'Dell S., Nason M., Lapedes A., Bhattacharya T., Migueles S.A., Wyatt R.T., Korber B.T., Mascola J.R., Connors M. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 2010, 84:1631-1636.
112. Banerjee K., Klasse P.J., Sanders R.W., Pereyra F., Michael E., Lu M., Walker B.D., Moore J.P. IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res. Hum. Retroviruses 2010, 26:445-458.
113. Mattapallil J.J., Douek D.C., Hill B., Nishimura Y., Martin M., Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005, 434:1093-1097.
114. Li Q., Duan L., Estes J.D., Ma Z.M., Rourke T., Wang Y., Reilly C., Carlis J., Miller C.J., Haase A.T. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005, 434:1148-1152.
115. Mehandru S., Poles M.A., Tenner-Racz K., Horowitz A., Hurley A., Hogan C., Boden D., Racz P., Markowitz M. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 2004, 200:761-770.
116. Brenchley J.M., Price D.A., Schacker T.W., Asher T.E., Silvestri G., Rao S., Kazzaz Z., Bornstein E., Lambotte O., Altmann D., Blazar B.R., Rodriguez B., Teixeira-Johnson L., Landay A., Martin J.N., Hecht F.M., Picker L.J., Lederman M.M., Deeks S.G., Douek D.C. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 2006, 12:1365-1371.
117. Sankaran S., Guadalupe M., Reay E., George M.D., Flamm J., Prindiville T., Dandekar S. Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc. Natl. Acad. Sci. USA 2005, 102:9860-9865.
118. Ferre A.L., Lemongello D., Hunt P.W., Morris M.M., Garcia J.C., Pollard R.B., Yee H.F., Martin J.N., Deeks S.G., Shacklett B.L. Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers. J. Virol. 2010, 84:10354-10365.
119. Ferre A.L., Hunt P.W., Critchfield J.W., Young D.H., Morris M.M., Garcia J.C., Pollard R.B., Yee H.F., Martin J.N., Deeks S.G., Shacklett B.L. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009, 113:3978-3989.
120. Hunt P.W., Brenchley J., Sinclair E., McCune J.M., Roland M., Page-Shafer K., Hsue P., Emu B., Krone M., Lampiris H., Douek D., Martin J.N., Deeks S.G. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 2008, 197:126-133.
121. Hsue P.Y., Hunt P.W., Schnell A., Kalapus S.C., Hoh R., Ganz P., Martin J.N., Deeks S.G. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009, 23:1059-1067.
122. Sedaghat A.R., Rastegar D.A., O'Connell K.A., Dinoso J.B., Wilke C.O., Blankson J.N. T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors. Clin. Infect. Dis. 2009, 49:1763-1766.
123. Thompson M.A., Aberg J.A., Cahn P., Montaner J.S., Rizzardini G., Telenti A., Gatell J.M., Gunthard H.F., Hammer S.M., Hirsch M.S., Jacobsen D.M., Reiss P., Richman D.D., Volberding P.A., Yeni P., Schooley R.T. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 304:321-333.
124. Okulicz J.F., Grandits G.A., Weintrob A.C., Landrum M.L., Ganesan A., Crum-Cianflone N.F., Agan B.K., Marconi V.C. CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy. Clin. Infect. Dis. 2010, 50:1187-1191.
125. Brenchley J.M., Silvestri G., Douek D.C. Nonprogressive and progressive primate immunodeficiency lentivirus infections. Immunity 2010, 32:737-742.
126. Mudd P.A., Watkins D.I. Understanding animal models of elite control: windows on effective immune responses against immunodeficiency viruses. Curr. Opin. HIV AIDS 2011, 6:197-201.
127. Giraldo-Vela J.P., Rudersdorf R., Chung C., Qi Y., Wallace L.T., Bimber B., Borchardt G.J., Fisk D.L., Glidden C.E., Loffredo J.T., Piaskowski S.M., Furlott J.R., Morales-Martinez J.P., Wilson N.A., Rehrauer W.M., Lifson J.D., Carrington M., Watkins D.I. The major histocompatibility complex class II alleles Mamu-DRB1*1003 and -DRB1*0306 are enriched in a cohort of simian immunodeficiency virus-infected rhesus macaque elite controllers. J. Virol. 2008, 82:859-870.
128. Sacha J.B., Giraldo-Vela J.P., Buechler M.B., Martins M.A., Maness N.J., Chung C., Wallace L.T., Leon E.J., Friedrich T.C., Wilson N.A., Hiraoka A., Watkins D.I. Gag- and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc. Natl. Acad. Sci. USA 2009, 106:9791-9796.
129. Limou S., Le Clerc S., Coulonges C., Carpentier W., Dina C., Delaneau O., Labib T., Taing L., Sladek R., Deveau C., Ratsimandresy R., Montes M., Spadoni J.L., Lelievre J.D., Levy Y., Therwath A., Schachter F., Matsuda F., Gut I., Froguel P., Delfraissy J.F., Hercberg S., Zagury J.F. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J. Infect. Dis. 2009, 199:419-426.
130. Rotger M., Dalmau J., Rauch A., McLaren P., Bosinger S.E., Martinez R., Sandler N.G., Roque A., Liebner J., Battegay M., Bernasconi E., Descombes P., Erkizia I., Fellay J., Hirschel B., Miro J.M., Palou E., Hoffmann M., Massanella M., Blanco J., Woods M., Gunthard H.F., de Bakker P., Douek D.C., Silvestri G., Martinez-Picado J., Telenti A. Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J. Clin. Investig. 2011, 121:2391-2400.
131. Koup R.A., Graham B.S., Douek D.C. The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nat. Rev. Immunol. 2011, 11:65-70.
132. Horton R.E., McLaren P.J., Fowke K., Kimani J., Ball T.B. Cohorts for the study of HIV-1-exposed but uninfected individuals: benefits and limitations. J. Infect. Dis. 2010, 202(Suppl. 3):S377-381.
133. Lederman M.M., Alter G., Daskalakis D.C., Rodriguez B., Sieg S.F., Hardy G., Cho M., Anthony D., Harding C., Weinberg A., Silverman R.H., Douek D.C., Margolis L., Goldstein D.B., Carrington M., Goedert J.J. Determinants of protection among HIV-exposed seronegative persons: an overview. J. Infect. Dis. 2010, 202(Suppl. 3):S333-338.